Detalhe da pesquisa
1.
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med
; 389(24): 2256-2266, 2023 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870955
2.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
N Engl J Med
; 385(13): 1196-1206, 2021 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551229
3.
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.
J Transl Med
; 21(1): 265, 2023 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37072748
4.
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022).
J Transl Med
; 21(1): 488, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37475035
5.
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.
J Transl Med
; 20(1): 179, 2022 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35449104
6.
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
J Transl Med
; 20(1): 391, 2022 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36058945
7.
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
Lancet Oncol
; 22(12): 1692-1704, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34774225
8.
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
N Engl J Med
; 379(8): 722-730, 2018 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30134131
9.
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020.
J Transl Med
; 19(1): 142, 2021 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827575
10.
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
Invest New Drugs
; 39(4): 1057-1071, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33624233
11.
Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma.
J Am Acad Dermatol
; 84(2): 312-320, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31954753
12.
Improved survival in women versus men with merkel cell carcinoma.
J Am Acad Dermatol
; 84(2): 321-329, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32423829
13.
Intratumoral Immunotherapy-Update 2019.
Oncologist
; 25(3): e423-e438, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162802
14.
The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.
J Transl Med
; 18(1): 171, 2020 04 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32299446
15.
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.
Invest New Drugs
; 38(3): 844-854, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31385109
16.
The association between facility volume and overall survival in patients with Merkel cell carcinoma.
J Surg Oncol
; 122(2): 254-262, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32297324
17.
Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data.
Jpn J Clin Oncol
; 50(7): 800-809, 2020 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32083295
18.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Nature
; 515(7528): 563-7, 2014 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-25428504
19.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Lancet Oncol
; 20(9): 1239-1251, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31345627
20.
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Lancet Oncol
; 20(8): 1083-1097, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31221619